Ignite Creation Date:
2024-05-05 @ 4:39 PM
Last Modification Date:
2024-10-26 @ 9:22 AM
Study NCT ID:
NCT00280540
Status:
COMPLETED
Last Update Posted:
2010-11-09
First Post:
2006-01-19
Brief Title:
Efficacy and Safety of ValsartanHydrochlorothiazide Combination Therapy in Patients With Hypertension
Sponsor:
Novartis
Organization:
Novartis
Study Overview
Official Title:
A 6-week Treatment Regimen Study to Evaluate the Efficacy of Initial High Dose Valsartan Monotherapy 160 mg or Combo Therapy Valsartan Hydrochlorothiazide 160125 mg to Conventional Low-dose Valsartan Monotherapy 80 mg in Managing Patients With Hypertension
Status:
COMPLETED
Status Verified Date:
2008-03
Last Known Status:
None
Delayed Posting:
No
If Stopped, Why?:
Not Stopped
Has Expanded Access:
No
If Expanded Access, NCT#:
N/A
Has Expanded Access, NCT# Status:
N/A
Acronym:
None
Brief Summary:
This is a double-blind study to evaluate the reduction in systolic blood pressure using a therapy initiated with valsartan 160 mg or valsartan hydrochlorothiazide HCTZ 160125 mg compared to a more conventional approach therapy initiated with low-dose valsartan 80 mg
Detailed Description:
None
Study Oversight
Has Oversight DMC:
None
Is a FDA Regulated Drug?:
None
Is a FDA Regulated Device?:
None
Is an Unapproved Device?:
None
Is a PPSD?:
None
Is a US Export?:
None
Is an FDA AA801 Violation?:
None